Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005989 · ClinicalTrials.gov registry record · Phase 2

R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer

A Phase 2 study of Lung Cancer, sponsored by Mayo Clinic.

Completed
Registry status
Phase 2
Development phase
3
Study locations

NCT00005989: Completed Phase 2 study of Lung Cancer, sponsored by Mayo Clinic.

NCT00005989 is a Phase 2 study of Lung Cancer that has completed, run by Mayo Clinic. The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005989, a Phase 2 study of Lung Cancer, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 2
Development phase
3
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have recurrent or metastatic non-small cell lung cancer.

Conditions Studied

Lung Cancer

Interventions

  • DRUG tipifarnib

Study Locations (3)

Florida

  • Mayo Clinic in Florida - Jacksonville

Illinois

  • University of Chicago Cancer Research Center - Chicago

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Start Date 2002-11
Est. Completion 2007-07
Phase Phase 2

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00005989

The ClinicalTrials.gov registry entry for NCT00005989 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which tipifarnib is the first listed.

NCT00005989 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Illinois, Minnesota.

Frequently Asked Questions

What is clinical trial NCT00005989 about?

NCT00005989 is a clinical study titled "R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have recurrent or metastatic non-small cell lung cancer.

What is the current status of trial NCT00005989?

This trial is currently completed. It is a Phase 2 study. The study started on 2002-11. Estimated completion is 2007-07.

What conditions does trial NCT00005989 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT00005989?

The interventions under investigation include: tipifarnib (DRUG).

Who is sponsoring clinical trial NCT00005989?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00005989 being conducted?

This trial has 3 study locations across Florida, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.